Vanda Pharmaceuticals, Inc. (VNDA) – The value in this company is purely in its growth prospects. Trading near its 52-week low, and having missed earnings in a release in early August, this may be an excellent buying opportunity if the company is able to turn itself around. Furthermore, given the attractiveness of its lead drug in the effective treatment of schizophrenia, the company may become an acquisition target. With a microcap market capitalization and average daily trading volume around 150,000 shares per day, investors should take care in this name.
News 
Market Data 
Discover 
